The insights gathered through these analyses suggest that the expression levels of immunoproteasome subunits PSMB8 and PSMB9 can serve as biomarkers for predicting survival of melanoma patients and for identifying patients likely to favorably respond to immune-checkpoint inhibitors. Here, PSMB9 is linked to melanoma.